

SUBJECT TO CHANGE, SCAN
THE QR CODE FOR THE LATEST
UPDATES IN THE PROGRAM!



Program Wednesday 25th of September

Registration from 9.00 am

OPENING SESSION (Moderators: Magnus Gisslén, Nina Weis)

10.15-10.20 **Welcome – Magnus Gisslén, Sweden**

10.20-10.50 Opening Plenary (Plenary 1): **HIV-1 Transmission and spread in Sub-Saharan Africa**
– Christophe Fraser, United Kingdom

10.50-11.00 Discussion

PLENARY SESSION I – EPIDEMIOLOGY (Moderators: Magnus Gisslén, Nina Weis)

11.00-11.30 Plenary 2: **Phylogenetic evolution and spread of HIV-1 subtype A6 from Ukraine** – Miłosz Parczewski, Poland

11.30-11.40 Discussion

11.40-12.10 Plenary 3: **Current and future perspectives on INSTI resistance: Globally and Regionally**
– Annemarie Wensing, the Netherlands

12.10-12.20 Discussion

12.20-13.20 **Lunch**

ABSTRACT SESSION I (10 + 5 min discussion) (Moderators: Leo Flamholz, Aylin Yilmaz)

13.20-13.35 Oral 1: **Differing effects of TDF versus TAF on duodenal mucosa may explain their different effects on body weight and plasma lipid concentrations**, Jussi Sutinen, Finland

13.35-13.50 Oral 2: **People living with HIV exhibit distinct HIV DNA distribution in gut tissues relative to gut damage**, Hanne H Gullaksen, Norway

PLENARY SESSION II – ANTIVIRAL TREATMENT AND RESISTANCE (Moderators: Leo Flamholz, Aylin Yilmaz)

13.50-14.20 Plenary 4: **Novel antiretroviral therapies**
– Chloe Orkin, United Kingdom

14.20-14.30 Discussion

14.30-15.10 Plenary 5: **Resistance test tools and their application in clinical routine** – Rolf Kaiser and Martin Pirkel, Germany

15.10-15.20 Discussion

15.20-15.50 **Coffee break in exhibition/posters area**

PLENARY SESSION III – COVID-19 (Moderators: Sara Cajander, Jan Gerstoft)

15.50-16.20 Plenary 6: **Post-Covid conditions in relation to other post-infectious conditions** – Anders Hviid, Denmark

16.20-16.30 Discussion

16.30-17.00 Plenary 7: **Neuro-Covid** – Arvid Edén, Sweden

17.00-17.10 Discussion

PLENARY SESSION IV – HIV PERSISTENCE AND CURE (Moderators: Sara Cajander, Jan Gerstoft)

17.10-17.50 Plenary 8: **The potential role of bNAbs for HIV remission and cure** – Michel Nussenzweig, USA

17.50-18.00 Short break

18.00-19.00 **SATELLITE SYMPOSIUM I – GSK**

Long-acting injectable antiretroviral agents for HIV – current experiences and looking ahead
– Chloe Orkin, United Kingdom

19.00- **Poster Exhibition / Mingle**

Program Thursday 26th of September

08.00-08.55 SATELLITE SYMPOSIUM II – GILEAD

Turning the tide on hepatitis D

Speaker: Prof. Dr. Med. Markus Cornberg, Germany

PLENARY SESSION IV – HIV PERSISTENCE AND CURE (cont) (Moderators: Annika Karlsson, Anders Sönnernborg)

09.00-09.30 Plenary 9: HIV Cure: Where are we and do we have a map – Daniel Douek, USA

09.30-09.40 Discussion

09.40-10.10 Plenary 10: Measurement of the HIV reservoir and ATI in cure study design – Linos Vandekerckhove, Belgium

10.10-10.20 Discussion

10.20-10.50 *Coffee break in exhibition/posters area*

10.50-11.20 Plenary 11: Reservoir dynamics following ART regimen switch: Possible mechanisms and implications
– Ronald Moses Galiwango, Uganda

11.20-11.30 Discussion

ABSTRACT SESSION II (10 + 5 min discussion) (Moderators: Christina Carlander, Dag Henrik Reikvam)

11.30-11.45 Oral 3: Physical, psychosocial and sexual health among people aged 50 years and above, with and without HIV, in Denmark: a cross-sectional nationwide study, Ditte Scofield, Denmark

11.45-12.00 Oral 4: The impact of two-year Metformin treatment on CD4 T cell count and CD4/CD8 ratio in people living with HIV: A retrospective cohort study, Tintin Bäckdahl, Sweden

12.00-13.00 *Lunch*

POSTER SESSION (5 minutes for each presentation, followed by Q&A) (Moderators: Henna Rautiainen, Magnús Gottfreðsson)

Poster 1: The prevalence and characteristics of hepatitis B/D in 48,522 HBsAg tested individuals in Mongolia, Ganbolor Jargalsaikhan, Mongolia

Poster 2: Public knowledge and attitudes on HIV/AIDS in the U=U Era: Insights from a Nordic Survey Study, Ellen Moseholm, Denmark

Poster 3: Impact of BK polyomavirus origin in kidney transplant recipients, Justina Zigmantaviciute, Sweden

PLENARY SESSION V – CO-MORBIDITIES, INFLAMMATION AND COMPLICATIONS IN HIV INFECTION

13.40-14.10 Plenary 12: Potential consequences of chronic immune activation in HIV infection – Alan Winston, United Kingdom

14.10-14.20 Discussion

14.20-14.50 Plenary 13: The significance of gut mucosal integrity for immunological restoration in HIV
– Malin Meyer-Myklestad, Norway

14.50-15.00 Discussion

15.00-15.30 *Coffee break in exhibition/posters area*

PLENARY SESSION V – (cont) (Moderators: Helene Mens, Jussi Sutinen)

15.30-16.00 Plenary 14: Decreasing the risk of cardiovascular disease in HIV, insights from REPRIEVE? – Lene Ryom, Denmark

16.00-16.10 Discussion

16.10-16.40 Plenary 15: Screening for anal cancer – Who, When, and How? – Christina Carlander, Sweden

16.40-16.50 Discussion

ABSTRACT SESSION III (10 + 5 min discussion) (Moderators: Soo Aleman, Henna Rautiainen)

16.50-17.05 Oral 5: Distinct transcriptomic signatures of immune cells characterise disease control in patients with chronic hepatitis B, Åsa D. Apol, Denmark

17.05-17.20 Oral 6: Hepatic flares after nucleos(t)ide analogue cessation in HBeAg-negative hepatitis B: results from the Nuc-Stop Study, Marte Holmberg, Norway

17.20-17.30 *Short break*

17.30-18.30 SATELLITE SYMPOSIUM III – GILEAD

HIV drug resistance — An emerging concern?

Moderator: Anders Sönnernborg, Sweden

Speakers: Georg Behrens, Germany and Ole Kirk, Denmark

19.30- *Conference dinner*



SUBJECT TO CHANGE, SCAN
THE QR CODE FOR THE LATEST
UPDATES IN THE PROGRAM!



Program Friday 27th of September

08.00-08.55 SATELLITE SYMPOSIUM IV– GILEAD

Nordic expert discussion: Finding the remaining hepatitis C patients

Panel members:

Soo Aleman, Sweden, Henna Rautiainen, Finland, Anne Øvrehus, Denmark, Kristian B. Malme, Norway and Magnús Gottfreðsson, Iceland

PLENARY SESSION VIII – EMERGING INFECTIONS (Moderators: Sara Cajander, Magnus Gisslén)

09.00-09.30 Plenary 16: – From a goose in Guandong to dairy cattle in Texas:

The evolution of avian influenza over 30 years – Karl Ståhl, Sweden

09.30-09.40 Discussion

09.40-10.10 Plenary 17: Zoonotic potential of CWD and other prion diseases – Sylvie Benestad, Norway

10.10-10.20 Discussion

10.20-10.50 *Coffee break in exhibition/posters area*

PLENARY SESSION VIII – EMERGING INFECTIONS (cont)

10.50-11.20 Plenary 18: Mpox clade 1 emergence in DRC: Outbreak dynamics and viral evolution – Placide Mbala Kingebeni, DRC

11.20-11.30 Discussion

11.30-11.40 Nordic HIV & Virology Conference 2024 Abstract Awards – Moderator: Karin Pettersson, Sweden

PLENARY SESSION IX – HEPATITIS (Moderators: Soo Aleman, Nina Weis)

11.40-12.10 Plenary 19: The clinical implications of quantitative HBsAg – Maurizia Brunetto, Italy

12.10-12.20 Discussion

12.20-13.20 *Lunch*

PLENARY SESSION IX – HEPATITIS (cont)

13.20-13.50 Plenary 20: Biological insight through clinical responses to novel HBV/HDV drugs – Stephan Urban, Germany

13.50-14.00 Discussion

14.00-14.30 Plenary 21: The interaction of HBV with the immune system and the responses to antiviral therapy – Niklas Björkström, Sweden

14.30-14.40 Discussion

14.40-15.10 Plenary 22: New EASL guideline on the management of HBV infection – Markus Cornberg, Germany

15.10-15.20 Discussion

15.20-15.50 Plenary 23: The evolutionary journey of Hepatitis B over ten millennia – Arthur Kocher, Germany

15.50-16.00 Discussion

16.00-16.15 Concluding remarks – Nina Weis, Denmark